Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity
ACS Chemical Biology · 2024
DOI: 10.1021/acschembio.3c00568 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, 2024. Verfasst von Max J Bedding und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Health and Medical Research Council, Australian Research Council, New South Wales COVID-19 Research Grant.
Abstract (Originalsprache)
The development of effective antiviral compounds is essential for mitigating the effects of the COVID-19 pandemic. Entry of SARS-CoV-2 virions into host cells is mediated by the interaction between the viral spike (S) protein and membrane-bound angiotensin-converting enzyme 2 (ACE2) on the surface of epithelial cells. Inhibition of this viral protein-host protein interaction is an attractive avenue for the development of antiviral molecules with numerous spike-binding molecules generated to date. Herein, we describe an alternative approach to inhibit the spike-ACE2 interaction by targeting the spike-binding interface of human ACE2 via mRNA display. Two consecutive display selections were performed to direct cyclic peptide ligand binding toward the spike binding interface of ACE2. Through this process, potent cyclic peptide binders of human ACE2 (with affinities in the picomolar to nanomolar range) were identified, two of which neutralized SARS-CoV-2 entry. This work demonstrates the potential of targeting ACE2 for the generation of anti-SARS-CoV-2 therapeutics as well as broad spectrum antivirals for the treatment of SARS-like betacoronavirus infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
- Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, New South Wales 2006, Australia.
- School of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
- Kirby Institute, Sydney, New South Wales 2052, Australia.
- Sydney Analytical Core Research Facility, The University of Sydney, Sydney, New South Wales 2006, Australia.
- School of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
ORCID-Profile: Karishma Patel, Jason K K Low, Toby Passioura, Richard J Payne
Förderung
- National Health and Medical Research Council
- Australian Research Council
- New South Wales COVID-19 Research Grant
- NSW Vaccine Infection and Immunology Collaborative
Zitieren
APA
Bedding, M. J., Franck, C., Johansen-Leete, J., Aggarwal, A., Maxwell, J. W. C., Patel, K., Hawkins, P. M. E., Low, J. K. K., Siddiquee, R., Sani, H. M., Ford, D. J., Turville, S., Mackay, J. P., Passioura, T., Christie, M., & Payne, R. J. (2024). Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00568
Vancouver
Bedding MJ, Franck C, Johansen-Leete J, Aggarwal A, Maxwell JWC, Patel K, et al. Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity. ACS Chemical Biology. 2024. doi:10.1021/acschembio.3c00568
BibTeX
@article{Bedding2024,
author = {Bedding, Max J and Franck, Charlotte and Johansen-Leete, Jason and Aggarwal, Anupriya and Maxwell, Joshua W C and Patel, Karishma and Hawkins, Paige M E and Low, Jason K K and Siddiquee, Rezwan and Sani, Hakimeh Moghaddas and Ford, Daniel J and Turville, Stuart and Mackay, Joel P and Passioura, Toby and Christie, Mary and Payne, Richard J},
title = {Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity},
journal = {ACS Chemical Biology},
year = {2024},
doi = {10.1021/acschembio.3c00568}
}
EUVIMED